Revenue
2022
2023
2024
2025
NewAmsterdam Pharma Co N.V. (NAMS)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $22.5M | $45.6M | $14.1M | $102.7M | — |
| Research & development | $141.8M | $151.4M | $159.4M | $86.7M | $29.0M |
| Operating expenses | $248.2M | $221.9M | $197.1M | $106.3M | $35.0M |
| Operating income | −$225.7M | −$176.3M | −$183.0M | −$3.6M | −$35.0M |
| EBITDAderived | −$225.5M | −$176.2M | −$182.9M | −$3.5M | −$35.0M |
| Net income | −$203.8M | −$241.6M | −$176.9M | −$22.6M | −$41.8M |
| Basic EPSper diluted share | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 |
| Diluted EPSper diluted share | -$1.72 | -$2.56 | -$2.15 | -$1.19 | -$3.81 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 22, 2026Form 4 · 10b5-1 | Kooij Louise FrederikaChief Accounting Officer | SellOrdinary Shares | 300 | $30.73 | $9.2K | 24.4K |
| Jun 22, 2026Form 4 · 10b5-1 | Kooij Louise FrederikaChief Accounting Officer | SellOrdinary Shares | 39.7K | $30.20 | $1.20M | 24.7K |
| May 26, 2026Form 4 · 10b5-1 | Kooij Louise FrederikaChief Accounting Officer | SellOrdinary Shares | 65.0K | $35.69 | $2.32M | 24.4K |
| Mar 11, 2026Form 4 | LANGE LOUIS GDirector | SellOrdinary Shares | 446 | $31.23 | $13.9K | 10.4K |
| Mar 11, 2026Form 4 | LANGE LOUIS GDirector | SellOrdinary Shares | 44.2K | $30.41 | $1.34M | 10.8K |